Scarica l'app Stockscreener
0.8969
3.08%
0.0268
Dopo l'orario di chiusura:
.90
0.0031
+0.35%
Precedente Chiudi:
$0.8701
Aprire:
$0.845
Volume 24 ore:
138.73K
Relative Volume:
0.73
Capitalizzazione di mercato:
$25.96M
Reddito:
$26.55M
Utile/perdita netta:
$-91.72M
Rapporto P/E:
-0.2503
EPS:
-3.584
Flusso di cassa netto:
$-13.25M
1 W Prestazione:
+11.26%
1M Prestazione:
-19.20%
6M Prestazione:
-54.70%
1 anno Prestazione:
-60.83%
Intervallo 1D:
$0.845
$0.92
Intervallo di 1 settimana:
$0.80
$0.92
Portata 52W:
$0.7101
$4.35
Celularity Inc Stock (CELU) Company Profile
Nome
Celularity Inc
Settore
Industria
Telefono
(908) 768-2170
Indirizzo
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.8969 | 25.19M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-30 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-06 | Downgrade | Truist | Buy → Hold |
| 2022-01-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Celularity Inc Borsa (CELU) Ultime notizie
Why Is Celularity Inc. (GXGX) Stock Up Today? - Meyka
Why Is Celularity Inc. (GXGXW) Stock Down Today? - Meyka
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (NASDAQ: CELU) notifies SEC of delayed Q1 2026 10-Q - Stock Titan
NexGel Q1 2026 Earnings Call Transcript - MarketBeat
TradingKey - TradingKey
Sequence execs join NEXGEL (NASDAQ: NXGL) board after $5.5M note deal - Stock Titan
The margin expansion playbook at Celularity (CELUW) | CELUW QX Earnings: Celularity Reports with No Revenue DataExpert Breakout Alerts - Newser
The hidden strength in Celularity (CELU) most investors miss (Underperforming) 2026-05-07Viral Trades - Newser
Celularity regains Nasdaq compliance after delayed filing - MSN
After $5.5M deal backing, Sequence executives take 2 NEXGEL board seats - Stock Titan
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - The Manila Times
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity Regains Nasdaq Listing Compliance, Shares Rise - marketscreener.com
Celularity regains Nasdaq compliance after filing annual report By Investing.com - Investing.com Australia
Celularity regains Nasdaq compliance after filing annual report - Investing.com
Nasdaq closes Celularity listing case after delayed 10-K filing - Stock Titan
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) - marketscreener.com
[10-K] Celularity Inc Files Annual Report - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Celularity Inc FY 2025: Revenue $26.6M, EPS $(3.59) — 10-K Summary - TradingView
10-K: FY2025 Annual Report - Moomoo
Celularity Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Celularity (CELU) Registration Filing Summary - Quartr
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
Nexgel, Inc. Appoints Ian Blackman as Chief Financial Officer - marketscreener.com
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Xã Châu Thành
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Secondary Offering - Xã Thanh Hà
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
Celularity Inc Azioni (CELU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celularity Inc Azioni (CELU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):